Candel Therapeutics Inc Stock

$5.27

5.39% today

Nasdaq, Apr 02, 09:50 pm CET

ISIN

US1374041093

Symbol

CADL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Candel Therapeutics Inc Stock price

$5.31

-1.69 24.14% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

-0.26 4.67%

ISIN

US1374041093

Symbol

CADL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$263.10m
Enterprise Value	$173.92m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	3.94
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-33.37m
Free Cash Flow (TTM) Free Cash Flow	$-27.04m
Cash position	$102.65m
EPS (TTM) EPS	$-1.75
P/E forward	negative
Short interest	8.06%

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Get Started for Free Today

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Candel Therapeutics Inc forecast:

4x Buy

100%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Candel Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.99 0.99	18% 18% -
Gross Profit	-0.99 -0.99	18% 18% -
- Selling and Administrative Expenses	13 13	3% 3% -
- Research and Development Expense	18 18	21% 21% -
EBITDA	-32 -32	13% 13% -
- Depreciation and Amortization	0.99 0.99	18% 18% -
EBIT (Operating Income) EBIT	-33 -33	13% 13% -
Net Profit	-55 -55	45% 45% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Candel Therapeutics Inc Stock News

Positive

Proactive Investors

●

one day ago

Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409

Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a particularly aggressive form of brain cancer. The study, published in Neuro-Oncology, found that CAN-2409, when combined with the immunotherapy drug nivolumab and standard treatments like surgery, ra...

Neutral

GlobeNewsWire

●

one day ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care

Positive

Proactive Investors

●

4 days ago

Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI

Candel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said the study enrolled patients who had exhausted standard treatment options, including chemotherapy and checkpoint inhibitors.

More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office	United States
CEO	Paul-Peter Tak
Employees	38
Founded	2002
Website	www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now